Renal microcirculatory effects of lovastatin in a rat model of reduced renal mass

被引:14
作者
Glazer, AA
Inman, SR
Stowe, NT
Novick, AC
机构
[1] CLEVELAND CLIN FDN,DEPT UROL,CLEVELAND,OH 44195
[2] LOYOLA UNIV,MED CTR,MAYWOOD,IL 60153
关键词
D O I
10.1016/S0090-4295(97)00338-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives, Patients with reduced renal mass are at increased risk of developing renal failure. A remnant kidney model has been used to study the hemodynamic and structural changes that occur, We recently reported that the lipid-lowering agent lovastatin preserves renal function in this model. The purpose of the present study was to determine the specific effects of lovastatin on the renal microcirculation of rats with reduced renal mass. Methods. We used the rat hydronephrotic kidney preparation with a 5/6 partial nephrectomy. This model allows direct visualization of preglomerular and postglomerular vessels using videomicroscopy, The diameters and vascular responses to acetylcholine and angiotensin II of the interlobular, afferent, and efferent vessels were determined in two groups of animals with renal mass reduction: 15 rats with no lovastatin treatment and 18 rats treated with oral lovastatin (15 mg/kg body weight/day) for 2 weeks. Results. In the lovastatin-treated rats, the baseline efferent vessel diameter was smaller by 21% (P < 0.05), but the interlobular and afferent vessel baseline diameters were not different from those in the untreated rats. Serum creatinine levels were lower in the treated rats (1.5 +/- 0.1 versus 2.0 +/- 0.2 mg/dL, P < 0.05), but serum lipids were not different. In the lovastatin-treated rats, vascular reactivity to acetylcholine was enhanced in the afferent and decreased in the efferent vessels. Conclusions. In this renal ablation model, lovastatin preserved renal function as measured by serum creatinine without lowering plasma lipid levels. Lovastatin treatment resulted in smaller efferent vessel diameters. Lovastatin also increased the vasodilatory response to acetylcholine in the afferent vessels, Together, these preglomerular and postglomerular changes would increase the single-nephron glomerular filtration rate. The renal protective effect of lovastatin may be due to these vasoactive effects on the renal microcirculation. (C) 1997, Elsevier Science Inc. All rights reserved.
引用
收藏
页码:812 / 817
页数:6
相关论文
共 28 条
[1]   THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].
ANDERSON, TJ ;
MEREDITH, IT ;
YEUNG, AC ;
FREI, B ;
SELWYN, AP ;
GANZ, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493
[2]  
[Anonymous], 1981, Statistical Tables
[3]   ROLE OF EDRF (NITRIC-OXIDE) IN DIABETIC RENAL HYPERFILTRATION [J].
BANK, N ;
AYNEDJIAN, HS .
KIDNEY INTERNATIONAL, 1993, 43 (06) :1306-1312
[4]   NEPHRON ADAPTATION TO RENAL INJURY OR ABLATION [J].
BRENNER, BM .
AMERICAN JOURNAL OF PHYSIOLOGY, 1985, 249 (03) :F324-F337
[5]   THE COMBINATION OF LOVASTATIN AND ENALAPRIL IN A MODEL OF PROGRESSIVE RENAL-DISEASE [J].
BROUHARD, BH ;
TAKAMORI, H ;
SATOH, S ;
INMAN, S ;
CRESSMAN, M ;
IRWIN, K ;
BERKLEY, V ;
STOWE, N .
PEDIATRIC NEPHROLOGY, 1994, 8 (04) :436-440
[6]  
DAMICO G, 1991, KIDNEY INT, V39, pS65
[7]   FOCAL AND SEGMENTAL GLOMERULOSCLEROSIS - ANALOGIES TO ATHEROSCLEROSIS [J].
DIAMOND, JR ;
KARNOVSKY, MJ .
KIDNEY INTERNATIONAL, 1988, 33 (05) :917-924
[8]  
FRETSCHNER M, 1991, RENAL PHYSIOL BIOCH, V14, P112
[9]   Renal hemodynamic effects of lovastatin in a renal ablation model [J].
Hafez, KS ;
Inman, SR ;
Stowe, NT ;
Novick, AC .
UROLOGY, 1996, 48 (06) :862-867
[10]   LOVASTATIN AMELIORATES THE DEVELOPMENT OF GLOMERULOSCLEROSIS AND UREMIA IN EXPERIMENTAL NEPHROTIC SYNDROME [J].
HARRIS, KPG ;
PURKERSON, ML ;
YATES, J ;
KLAHR, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 15 (01) :16-23